OPINION OF THE COURT
In this case we are called upon to determine whether a drug testing laboratory may be held liable in tort to the subject of a drug test for negligently testing that subject’s biological specimen notwithstanding the absence of a formal contractual relationship between the drug testing laboratory and the subject of the drug test. We answer the question in the affirmative.
The complaint in this action alleged that the defendant, Kroll Laboratory Specialists, Inc., was a Louisiana corporation which held a New York State Department of Health Laboratory Permit for Comprehensive Forensic Toxicology and which was in the business of performing forensic toxicology testing to determine the presence or absence of illicit or controlled substances. The defendant entered into a contract with the Orange County Probation Department to analyze oral fluid samples provided by individuals on probation.
On January 28, 2002, the plaintiff was convicted of forgery in the second degree in Orange County. The County Court sentenced the plaintiff to a five-year term of probation. As a condition of his sentence, the plaintiff was required to submit to periodic and random drug testing at the direction of his probation officer.
The plaintiff alleged that on December 17, 2007, while still serving his probationary sentence, he was directed by his probation officer to submit an oral fluid sample for the purpose of determining whether he was complying with the terms of his probation. An oral sample was taken by the plaintiff ‘s probation officer utilizing a device known as “the Intercept DO A Oral Specimen Collection Device” which was manufactured by Orasure Technologies, Inc. (hereinafter Orasure), and which had been purchased from the defendant for such purposes. The
Later that day on December 17, 2007, the plaintiff obtained an independent blood test, which revealed that the plaintiff’s blood sample was negative for illicit or controlled substances on December 17, 2007.
The complaint stated that the oral sample provided by the plaintiff was received at the defendant’s facility on December 20, 2007. Screening was performed in accordance with the defendant’s standard policy and practice utilizing a “Micro-Plate EIA,” a device also developed by Orasure. It was determined that the oral sample contained amounts of cannabinoids which exceeded the defendant’s screen test cutoff level of 1.0 ng/mL.
In a written report dated December 20, 2007, the defendant informed the Orange County Probation Department that the oral sample tested positive for marijuana. The complaint alleged that as a result of this erroneous report, the plaintiff’s probationary sentence was extended for months beyond the original term and he was compelled to make multiple court appearances to prevent his incarceration based on the erroneous test result.
The plaintiff claimed that the defendant utilized a screen test cutoff level of only 1.0 ng/mL despite the fact that Orasure, the manufacturer of the collection device and the developer of the testing method, recommended a screen test cutoff level of at least 3.0 ng/mL. Moreover, the complaint alleged that the industry-wide standard for forensic drug testing required a screen test cutoff level of 4.0 ng/mL.
In addition, the complaint alleged that the test performed by the defendant was never confirmed by use of a gas chromatography-mass spectrometry test (hereinafter a GC/MS test) or by any other method. The complaint further alleged that holders of a New York State Department of Health Laboratory Permit for Comprehensive Forensic Toxicology were required to utilize a GC/MS test before reporting a positive test result.
The defendant moved to dismiss the complaint asserting, among other things, that the plaintiff failed to state a cause of action. The Supreme Court granted that branch of the defendant’s motion and dismissed the complaint pursuant to CPLR 3211 (a) (7). We reverse the order insofar as appealed from.
“A party may move for judgment dismissing one or more causes of action asserted against [it] on the ground that. . . the
“Whether a plaintiff can ultimately establish its allegations is not part of the calculus in determining a motion to dismiss” (EBC I, Inc. v Goldman, Sachs & Co., 5 NY3d 11, 19 [2005]). Rather, a court must “determine only whether the facts as alleged fit within any cognizable legal theory” (Leon v Martinez,
The Court of Appeals has recognized that “the line separating tort and contract claims may be elusive [and] the classification . . . consequential” (Sommer v Federal Signal Corp.,
“Duty is essentially a legal term by which we express our conclusion that there can be liability” (De Angelis v Lutheran Med. Ctr.,
On the other hand, “[a] tort obligation is a duty imposed by law to avoid causing injury to others” (New York Univ. v Continental Ins. Co.,
A person is not necessarily insulated from liability in tort merely because he or she is engaged in performing a contractual obligation (see Rich v New York Cent. & Hudson Riv. R.R. Co.,
“The very nature of a contractual obligation, and the public interest in seeing it performed with reasonable care, may give rise to a duty of reasonable care in performance of the contract obligations, and the breach of that independent duty will give rise to a tort claim” (New York Univ. v Continental Ins. Co.,
In this regard “[professionals, common carriers and bailees, for example, may be subject to tort liability for failure to exercise reasonable care, irrespective of their contractual duties” (Sommer v Federal Signal Corp.,
Historically, “[o]ne of the earliest appearances of what we now know as negligence was in the liability of those who
Similarly, the Restatement (Second) of Torts recognizes that “[a]n act may be negligent if it is done without the competence which a reasonable man in the position of the actor would recognize as necessary to prevent it from creating an unreasonable risk of harm to another” (Restatement [Second] of Torts § 299). Thus the degree of care that a reasonably prudent person would use under the circumstances may be established through evidence of the general customs and practices of others who are in the same business or trade as that of the alleged tortfeasor (see Trimarco v Klein,
The complaint in this case alleges that the defendant undertook to perform forensic toxicology testing and that the
However, as it is often said, “ ‘[p]roof of negligence in the air, so to speak, will not do’ ” (Palsgraf v Long Is. R.R. Co.,
“Unlike foreseeability and causation, which are issues generally and more suitably entrusted to fact finder adjudication, the definition of the existence and scope of an alleged tortfeasor’s duty is usually a legal, policy-laden declaration reserved for Judges to make prior to submitting anything to fact-finding or jury consideration” (Palka v Servicemaster Mgt. Servs. Corp.,
“[D]uty is not something derived or discerned from an algebraic formula” (Palka v Servicemaster Mgt. Servs. Corp.,
“Duty in negligence cases is defined neither by foreseeability of injury . . . nor by privity of contract” (Strauss v Belle Realty Co.,
*86 “Contractual privity as the basis for defining the ambit of duty in negligence cases derives from the famous case of Winterbottom v Wright (10 M & W 109, 152 Eng Rep 402 [Ex 1842]), a suit by an injured coachman against the supplier of a coach whose defective wheel had caused him injury” (Ossining Union Free School Dist. v Anderson LaRocca Anderson,73 NY2d 417 , 421-422 [1989]; see Credit Alliance Corp. v Arthur Andersen & Co.,65 NY2d 536 , 546-547 [1985]).
In Winterbottom, recovery in tort was denied on the ground that there was no privity of contract between the injured coachman and the supplier of the defective wheel (see Winterbottom v Wright, 10 M & W at 114, 152 Eng Rep at 405 [Ex 1842]).
The courts of this state have long eschewed strict application of the privity requirement espoused in Winterbottom in actions involving physical injury (see MacPherson v Buick Motor Co.,
Whatever the nature of the injury however, the underlying rationale for inquiring into the issue of contractual privity in this context is a “deep concern about the widespread liability to which a [contractor] would be exposed without some circumscribing principle” (Ossining Union Free School Dist. v Anderson LaRocca Anderson,
Courts have utilized this concept of privity to “limit[ ] the universe of permissible plaintiffs because a failure to do so would impose a duty of reasonable care enforceable by any member of an indeterminate class of persons, present and prospective, known and unknown, directly or indirectly injured by any negligence” (Eiseman v State of New York,
Here, the prospect of limitless liability is extremely small. The duty alleged in the complaint relates only to a narrow class of specific and readily identifiable individuals whose biological samples were accepted and tested for the defined contractual purpose (cf. Palka v Servicemaster Mgt. Servs. Corp.,
The burden such liability would impose, whatever the magnitude, must nevertheless be weighed against the societal benefits resulting from the imposition of the alleged legal duty (see Peralta v Henriquez,
The importance attached to the results of drug tests can hardly be overstated. Indeed, the results of drug tests may form the basis for decisions affecting the very core of people’s lives. A positive test may result in the loss of current employment (see e.g. Matter of Kirk v City of New York,
These cases illustrate the extent to which the results of drug tests pervade numerous aspects of individuals’ lives. We also note a study by the United States Department of Health and Human Services which determined that an estimated 54 million full-time workers reported that their employer tested for illicit drug use and an estimated 38.7 million full-time workers reported that their employer conducted testing for alcohol use (see Larson et al., Worker Substance Use and Workplace Policies and Programs, Substance Abuse and Mental Health Services Administration, Office of Applied Studies [DHHS Publication No. SMA 07-4273, Analytic Series A-29], available at http:// www.samhsa.gov/data/work2k7/work.htm). Although these numbers are by no means definitive or comprehensive, they nevertheless serve to indicate the extent to which drug testing has proliferated since its relatively recent inception.
Given the importance drug testing holds in the management of modern affairs and the costs that inaccuracies may exact on society, it is paramount that incentives exist to minimize the risk of erroneous test results. However, we are unaware of any legislative remedies extended to test-subjects who are victims of negligent drug testing (see Drake v Laboratory Corp. of Am. Holdings,
Nor do we perceive adequate incentives in the operation of market forces. Drug testing has been described as “a multimillion dollar growth industry for test equipment manufacturers, laboratories, consultants, and even private physicians” (Rothstein, Workplace Drug Testing: A Case Study in the Misapplication of Technology, 5 Harv J Law & Tec 65, 87 [1991]). One past estimate of the cost of testing employees for drugs fixed the total at one billion dollars annually (see Lockard, Protecting Medical Laboratories from Tort Liability for Drug Testing, 17 J Legal Med 427, 427 [1996]).
We note that numerous other states have already recognized a duty running from a drug testing laboratory to a noncontracting individual whose biological specimen was tested for the presence of drugs {see Webster v Psychemedics Corp.,
In conclusion, we hold that a drug testing laboratory may be held liable in tort to the subject of a drug test for failing to use reasonable care under the circumstances, notwithstanding the absence of a formal contractual relationship between the drug testing laboratory and the subject of the drug test. Accordingly,
Angiolillo, J.P, Florio and Leventhae, JJ., concur.
Ordered that the order is reversed insofar as appealed from, on the law, with costs, and that branch of the defendant’s motion which was to dismiss the complaint pursuant to CPLR 3211 (a) (7) is denied.
